Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through ...

Engineered dendritic cells capture tumor EVs, enhancing antigen presentation and T cell activation to boost cancer immunotherapy in preclinical models.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity.

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Immune protection fades with time, and much of that decline traces back to the thymus. This small organ, located in front of the heart, trains new T cells and releases signals that help them survive.

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a ...

METiS TechBio ('METiS') today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...